$1.26
-0.01 (-0.79%)
Open$1.27
Previous Close$1.27
Day High$1.28
Day Low$1.24
52W High$3.08
52W Low$1.08
Volume—
Avg Volume774.1K
Market Cap72.09M
P/E Ratio4.73
EPS$0.17
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,387.3% upside
Current
$1.26
$1.26
Target
$31.34
$31.34
$21.51
$31.34 avg
$48.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 64.74M | 60.12M | 30.93M |
| Net Income | 8.31M | 6.94M | -5,880,957 |
| Profit Margin | 12.8% | 12.2% | -19.0% |
| EBITDA | 6.12M | 5.40M | -8,827,347 |
| Free Cash Flow | — | — | -6,633,459 |
| Rev Growth | +7.7% | +7.7% | +18.4% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |